Financial News

Nicox announces that its Exclusive Licensee Submits response to CRL for latanoprostene bunod ophthalmic solution, 0.024%

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced that its exclusive licensee has informed Nicox that it has submitted a response to the Complete Response Letter (CRL) received from the U.S. Food and Drug Administration (FDA) on August 7, 2017 concerning the New Drug Application (NDA) for latanoprostene bunod ophthalmic solution,

Read more

Shareholder Letter

Dear Nicox Shareholder,
You may have seen the announcement (attached) of our increase of capital dedicated to a specific category of investors and you might wonder why we did it just on the back of the very disappointing news of a further, unexpected delay on the decision regarding the approval of VYZULTA.
We at Nicox, the Board and the management,

Read more

Nicox announces €26.25 million financing

Not for distribution in or into the United States of America, Canada, Japan or Australia, except as permitted by applicable law
Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced a reserved capital increase of ordinary shares of the Company to a specific category of investors. The gross proceeds from the financing are €26.25 million,

Read more
More news